Aspen to purchase anaesthetics from AstraZeneca for US$520m
[JOHANNESBURG] Aspen Pharmacare Holdings Ltd said it would buy an anaesthetics portfolio from AstraZeneca Plc of the UK for at least US$520 million, the first acquisition by Africa's largest generic-drugs maker since securing new funding.
The South African company will also pay AstraZeneca royalties and as much as US$250 million in additional sales-based instalments over the next two years, Durban-based Aspen said in a statement on Thursday. It will gain seven established medicines sold in more than 100 countries that generate revenue of $592 million a year.
The company "has identified anaesthetics as a therapeutic category that presents the opportunity to add significant value," Aspen said. "The key territories in which the portfolio is sold represent an excellent fit with Aspen's existing operational geographic footprint."
The deal comes a day after Aspen said it had secured US$3.4 billion in funding, attracting support from 27 banks. The company has spent more than US$2 billion on acquisitions from drugmakers including GlaxoSmithKline Plc and Merck & Co in recent years to boost its portfolio of medicines and manufacturing sites, and now sells drugs in more than 150 countries.
Aspen shares have gained 3.7 per cent this year to 320.94 rand, valuing the business at US$9.9 billion. The drugmaker is South Africa's seventh-largest company by market capitalisation.
BLOOMBERG
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO